CCL2 and glioblastoma: In addition, deguelin not only inhibited the CCL2/NF-κB signaling pathway, but also exogenous supplementation of CCL2 could partially reverse the growth inhibitory effect of deguelin on GBM cells by upregulating NF-κB activity.